MarketPeel
Insider Trading Intelligence
MV

Michael Vasconcelles

KURA
DIRECTOR · KURA ONCOLOGY, INC. · CIK 0001734755
FILING MIX · LIFETIME56%/44%
BUYS
9
SELLS
7
TOTAL VALUE
$31.6K
COMPANIES
2
ACTIVE SINCE
Sep 2024
HOLDINGS NOW
35,000
AVG SELL PX
$11.60
TRADE KIND
SHOWING 16 / 16
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Michael Vasconcelles, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%+1.22%+0.66%+0.56%+0.56%
14d1+100.00%-15.65%-0.37%-15.29%-15.29%
30d1+0.00%+80.05%-3.38%+83.43%+83.43%
60d1+0.00%+80.72%+4.00%+76.73%+76.73%
90d1+8.71%
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KURA · 35,000 shares · as of Jun 4, 2026
013,00026,00039,00052,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 9 buys / 7 sellsCOVERAGE · 8 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
35,00035,000Jun 4, 2026Jun 4, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
SALE
Head of Research and Dev.
226,0000Apr 23, 2026Apr 23, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
SALE
Head of Research and Dev.
4,3970Apr 23, 2026Apr 23, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
SALE
Head of Research and Dev.
171,0000Apr 23, 2026Apr 23, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
SALE
Head of Research and Dev.
106,8750Apr 23, 2026Apr 23, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
SALE
Head of Research and Dev.
346,0000Apr 23, 2026Apr 23, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
SALE
Head of Research and Dev.
2,728$11.60$31.6K4,397Feb 17, 2026Feb 18, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
PURCHASE
Head of Research and Dev.
7,1257,125Feb 15, 2026Feb 18, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
SALE
Head of Research and Dev.
7,125106,875Feb 15, 2026Feb 18, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
171,000171,000Jan 30, 2026Jan 30, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
114,000114,000Jan 30, 2026Jan 30, 2026View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
346,000346,000Jun 16, 2025Jun 18, 2025View →
DAWN
DAY ONE BIOPHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
226,000226,000Jun 16, 2025Jun 18, 2025View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
28,50028,500Jun 5, 2025Jun 6, 2025View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
52,00052,000Sep 13, 2024Sep 17, 2024View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
17,33317,333Sep 13, 2024Sep 17, 2024View →
Other insiders · KURA
Loading peer insiders…
About this filer
CIK 0001734755
ROLE
Director
PRIMARY
KURA
COMPANIES
2
ACTIVE SINCE
Sep 2024
MARKETPEEL · /INSIDER/0001734755DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback